Back to Home
Health & Medicine · Global Industry

Pharmaceuticals — Numbers That Matter

A concise factsheet of the world's pharmaceutical industry: global market size, R&D spending, drug approval pipelines, and where the money flows. Every number links to a primary source.

Automation Progress

Technology Readiness
Lab Pilot Commercial Mature
Task Automation Rate
~8% of human tasks in this field
People Affected
~5M pharmaceutical workers worldwide
Growth Momentum
~28% CAGR AI in pharma market 2024–2030
Global Pharma Market Revenue (2024)
$1.48 trillion
The global pharmaceutical market reached an estimated $1.48 trillion in revenue in 2024, making it one of the largest industries worldwide. The market is projected to exceed $1.9 trillion by 2029.
Source: Statista — Global Pharmaceutical Industry Report (2025 edition); IQVIA — The Global Use of Medicines 2025
Global Pharma R&D Spending (2024)
~$252 billion
Pharmaceutical companies collectively invested approximately $252 billion in research and development in 2024, up from $244 billion in 2023. R&D intensity (as % of revenue) averages about 20–25% for the top 20 companies.
Source: IQVIA — Global Trends in R&D 2025; EFPIA — The Pharmaceutical Industry in Figures 2025
FDA Novel Drug Approvals (2024)
50 NMEs
The U.S. FDA approved 50 novel molecular entities (NMEs) in 2024, roughly in line with the five-year average. This includes 22 first-in-class drugs — medicines with entirely new mechanisms of action.
Source: FDA — Novel Drug Approvals for 2024
Average Cost to Develop One New Drug
~$2.3 billion
Including the cost of failures, it takes an estimated $2.3 billion on average to bring a single new drug from laboratory to market. The process typically spans 10–15 years from discovery to regulatory approval.
Source: DiMasi et al. (2016) — Journal of Health Economics; updated estimates from Deloitte Centre for Health Solutions (2024)

Revenue Breakdown by Therapeutic Area (2024)

22%
Oncology
~$223 B
11%
Immunology
~$167 B
9%
Diabetes & Obesity
~$133 B
58%
All Other Areas
~$957 B

Breakdown source: IQVIA — The Global Use of Medicines 2025; Evaluate — World Preview 2024

Top 10 Pharmaceutical Companies by Revenue (2024)

Revenue figures are for pharmaceutical segments only (excluding consumer health, medtech, etc. where applicable). Rankings may vary slightly by source due to scope differences.

Rank Company Pharma Revenue HQ Source
1 Johnson & Johnson $56.2 B 🇺🇸 US J&J 2024 Annual Report
2 Roche $49.2 B 🇨🇭 Switzerland Roche 2024 Annual Report
3 Pfizer $45.0 B 🇺🇸 US Pfizer 2024 Earnings
4 Novartis $44.4 B 🇨🇭 Switzerland Novartis 2024 Results
5 Merck & Co. $42.2 B 🇺🇸 US Merck 2024 Annual Report
6 AbbVie $40.6 B 🇺🇸 US AbbVie 2024 Annual Report
7 Eli Lilly $38.1 B 🇺🇸 US Eli Lilly 2024 Annual Report
8 Sanofi $35.5 B 🇫🇷 France Sanofi 2024 Results
9 AstraZeneca $34.1 B 🇬🇧 UK AstraZeneca 2024 Annual Report
10 Bristol-Myers Squibb $32.8 B 🇺🇸 US BMS 2024 Annual Report

Global Pharmaceutical Market Size (2020 – 2024)

Total worldwide pharmaceutical revenue including prescription and OTC medicines. Figures may vary slightly between sources (IQVIA, Evaluate, Statista) due to scope definitions.

Year Market Size YoY Change Source
2024 $1,480 B +5.8% IQVIA 2025
2023 $1,399 B +3.4% IQVIA 2024
2022 $1,352 B −2.1% IQVIA 2023
2021 $1,381 B +8.3% Statista
2020 $1,275 B +4.7% Statista

Top Pharmaceutical Markets by Country (2024)

Market size based on pharmaceutical spending (ex-manufacturer prices). Source: IQVIA — The Global Use of Medicines 2025

United States
$603 B
China
$166 B
Japan
$79 B
Germany
$63 B
France
$40 B
Italy
$33 B
United Kingdom
$32 B
Rest of World
$464 B

The United States alone accounts for roughly ~41% of global pharmaceutical revenue. The top 10 markets represent over 75% of the worldwide total.

Drug Development Pipeline — Key Numbers

Active Pipeline Candidates (Global)
~21,000 drugs
As of early 2025, over 21,000 drug candidates are in active development across all phases worldwide, including preclinical, Phase I–III, and pre-registration. Oncology leads with ~37% of the pipeline.
Source: Evaluate Pharma — World Preview 2024; Pharma Intelligence — R&D Annual Review 2024
Clinical Trial Success Rate (Phase I → Approval)
~7.9 %
Only about 1 in 13 drugs entering Phase I clinical trials ultimately win regulatory approval. Oncology has the lowest success rate (~5.3%), while vaccines and infectious disease drugs fare better (~15–22%).
Source: Wong et al. (2019) — Biostatistics; updated data from BIO — Clinical Development Success Rates 2011–2020

Top-Selling Drugs Worldwide (2024)

Revenue for individual branded drugs (or drug families). Rankings based on full-year 2024 sales reported by manufacturers.

Rank Drug Therapeutic Area 2024 Revenue Company
1 Keytruda (pembrolizumab) Oncology $27.3 B Merck
2 Ozempic / Wegovy (semaglutide) Diabetes / Obesity $25.8 B Novo Nordisk
3 Humira (adalimumab) Immunology $14.4 B AbbVie
4 Eliquis (apixaban) Cardiovascular $13.2 B BMS / Pfizer
5 Opdivo (nivolumab) Oncology $10.5 B BMS
6 Revlimid (lenalidomide) Oncology $9.8 B BMS
7 Biktarvy (bictegravir combo) HIV $9.5 B Gilead
8 Dupixent (dupilumab) Immunology $9.4 B Sanofi / Regeneron

Source: Compiled from individual company earnings reports and Evaluate Pharma — World Preview 2024. Revenue figures are approximate global sales.

All figures are rounded estimates reflecting the best available public data as of early 2025. "NME" refers to New Molecular Entity — a drug containing an active substance never previously approved. Pipeline counts include active Investigational New Drug (IND) applications across all therapeutic areas. Market size estimates vary between analytics providers (IQVIA, Evaluate, Statista) due to differences in scope (prescription-only vs. including OTC; ex-manufacturer vs. retail prices). For the most authoritative regulatory data, refer to the FDA Drug Approval Database, EMA Medicines Database, and China NMPA.